Delving into the Latest Updates on Mepolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Bosatria, Mepolizamab, Mepolizumab (Genetical Recombination)

+ [7]

Target

IL-5

Action

inhibitors

Mechanism

IL-5 inhibitors(Interleukin-5 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCardiovascular Diseases+ [5]

Active Indication

Pulmonary Disease, Chronic ObstructiveAsthmaChronic rhinosinusitis with nasal polyps+ [7]

Inactive Indication

Asthma, Nasal Polyps, and Aspirin IntoleranceDeglutition DisordersEosinophilic Esophagitis+ [5]

Originator Organization

GSK Plc

Active Organization

GlaxoSmithKline LLC

GSK PlcGlaxoSmithKline Trading Services Ltd.

+ [4]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (04 Nov 2015),

Severe asthma

RegulationFast Track (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (South Korea)

Login to view timeline

Structure/Sequence

Sequence Code 42934L

Source: *****

Sequence Code 43483H

Source: *****

The development of coronary atherosclerosis is closely related to inflammation, and CD147 may play an important role in its process. The present study was designed to evaluate the effects of long-term administration of mepolizumab (humanized anti-CD147 antibody) on lipid deposition and inflammation in coronary atherosclerotic plaques in patients with high-risk coronary artery disease, and to preliminarily explore the efficacy, safety, and dosage of long-term administration of mepolizumab in this population.

Start Date16 Oct 2024

Sponsor / Collaborator

Xijing Hospital

NCT06501807

/ Not yet recruitingNot ApplicableIIT

Real Life Assessment of Biologics Efficacy in Severe Chronic Rhinosinusitis With Nasal Polyps

With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So far, endoscopic sinus surgery remains the treatment of choice when the first line of medical treatment with corticosteroid has failed.
During the last 15 years, several studies have shown that CRSwNP is associated with a T helper 2 (T2) immune response leading to B cell release of IgE, mucosal recruitment of eosinophils from bone marrow via Interleukin (IL)-5, IL-4 and IL-13 mediated chemoattractant production.
New biologic agents capable of blocking T2 cytokines have been developed in the field of eosinophil-associated diseases, shifting the paradigm of treatment for patients with CRSwNP. In the near future, endotype profiling with accurate biomarkers will be mandatory to tailor the treatment of nasal polyposis with specific biologic therapies.
Herein the investigators propose a prospective study monitoring medical records of CRSwNP patients who undergo biologic treatments. The objectives are to assess treatment efficacy on quality of life, to report clinical and biological criteria for prescription and to measure tolerance and compliance.Patient-reported outcomes will be addressed according to their initial clinical profile (allergy, asthma, NSAID, gastroesophageal reflux disease, obstructive apnea, otologic disorder, smoke habit).

Start Date02 Sep 2024

Sponsor / Collaborator-

CTIS2023-508069-34-01

/ RecruitingPhase 4

Biomarkers for the prediction of individual CRSwNP patients' responses to mepolizumab

Start Date12 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Mepolizumab

Login to view more data

100 Translational Medicine associated with Mepolizumab

Login to view more data

100 Patents (Medical) associated with Mepolizumab

Login to view more data

1,642

Literatures (Medical) associated with Mepolizumab

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of mepolizumab vs anti-interleukin-5/5r biologic therapies for the treatment of adults with severe asthma with an eosinophilic phenotype: a Chilean healthcare system perspective

Article

Author: Romero, Jose ; Giovini, Vanina ; Espinoza, Manuel Antonio ; Balmaceda, Carlos ; Moraes dos Santos, Felipe ; Rodríguez Martínez, Consuelo

AIM:

Asthma is a heterogeneous respiratory condition often classified into distinct phenotypes. Severe asthma, characterized by uncontrolled symptoms despite optimal treatment, imposes a significant burden on healthcare systems, particularly in low- and middle-income countries. This study evaluates the cost-effectiveness of mepolizumab compared with other interleukin (IL)-5 pathway inhibitors, benralizumab and reslizumab, in treating severe asthma with an eosinophilic phenotype in Chile.

MATERIALS AND METHODS:

A Markov cohort model was developed to compare mepolizumab (100 mg subcutaneously every four weeks) with benralizumab (30 mg subcutaneously every four weeks for the first three doses, every eight weeks subsequently) and reslizumab (3 mg/kg intravenously every four weeks), both as add-on therapies to standard care. Data from the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) clinical trial and a network meta-analysis were used. Utility values were extracted using the EuroQoL 5-Dimension questionnaire (EQ-5D-5L) questionnaire. Probabilistic and one-way sensitivity analyses assessed model robustness.

RESULTS:

Mepolizumab demonstrated dominance with probability over 95% when compared with benralizumab and reslizumab. Cost savings ranged from 37,000 United States dollars (USD) to 104,000 USD, with an increase of 0.52 to 0.55 quality-adjusted life years. Mepolizumab was also associated with a lower incidence of exacerbations and asthma-related deaths. Sensitivity analyses confirmed the stability of the model outcomes across key parameters.

LIMITATIONS:

Limitations of the economic model are related to the lack of direct comparisons between mepolizumab and other biologics. Additionally, the absence of data on continuation criteria required estimating relative risks for the overall population.

CONCLUSIONS:

Mepolizumab offers greater efficacy and cost savings compared to benralizumab and reslizumab for eosinophilic asthma, providing essential insights for improving asthma management and informing healthcare policies in Chile.

01 Dec 2025·Current Cardiology Reports

Eosinophilic Myocarditis: A Concise Review

Review

Author: Kahwash, Rami ; Trovato, Vincenzo ; Asada, Ashlee M

Abstract:

Purpose of Review:

Eosinophilic myocarditis (EM) is a rare and heterogeneous form of inflammatory heart disease that can present with a wide range of severity. Current literature is limited to case reports or small case series that outline the evaluation process, disease course, and the nonstandardized treatments trialed. This review aims to concisely summarize the current literature on EM including an update on maintenance therapy for refractory or recurrent disease.

Recent Findings:

In the last several years, several observational studies have reported the clinical benefit of mepolizumab and benralizumab in refractory EM.

Summary:

EM is a complex and heterogenous cause of inflammatory heart disease with a wide range of etiologies and presentations. Treatment of this disease has not been standardized as there are no large scale trials quantifying benefit of any specific therapy regimen. Targeted biologics show promise in observational studies; therefore, prospective studies are needed to quantify this benefit in EM.

01 Dec 2025·CURRENT ALLERGY AND ASTHMA REPORTS

Olfactory Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Effect of Treatment with Emphasis on Biological Therapy

Review

Author: Reitsma, Sietze ; Fokkens, Wytske Johanna ; Otten, Josje Janna

PURPOSE OF REVIEW:

Olfactory dysfunction significantly impacts quality of life that affects a majority of the patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The aim of this review is to explore the impact of various treatment regimens on olfactory dysfunction in patients diagnosed with CRSwNP.

RECENT FINDINGS:

Accurate assessment of olfactory dysfunction remains challenging and should incorporate both psychophysical tests and patient-reported outcomes. Patients with CRSwNP appear capable of reliably evaluating their olfactory function. Standard treatment such as intranasal corticosteroids and surgery have limited capability of restoring the sense of smell. Oral corticosteroids have a far greater potency, albeit short-lived and at the cost of adverse events and side effects. Recent studies on registered biological agents- specifically dupilumab, mepolizumab, and omalizumab- indicate their effectiveness in restoring olfactory function in severe CRSwNP. According to meta-analyses and indirect comparisons, dupilumab shows superiority; however, direct comparative studies are necessary.

140

News (Medical) associated with Mepolizumab

03 Sep 2025

·pharma.economictimes.indiatimes.com

GST waiver for 36 drugs; formulations under 5% slab

New Delhi: Executing the much-awaited overhaul of the Goods and Services Tax (GST) regime, the GST Council has brought a major relief for patients by reducing the indirect tax on medicines to 5 per cent, along with exempting as many as 36 life-saving medicines and other critical drugs. The GST council—a statutory body highest decision making body on indirect taxes led by the Union Finance Ministry at its 56th meeting in the national capital has recommended to reduce the GST on all drugs and medicines (finished formulations) from 12 per cent to 5 per cent under the new two-tier tax structure of 5 and 18 per cent slabs to be effective from September 22. Additionally the body has also recommended to exempt GST on 33 lifesaving drugs and on 3 other medicines used for treatment of cancer, rare diseases and other severe chronic diseases. Speaking at a press briefing after the council 10.5-hour long marathon meet, Finance Minister Nirmala Sitharaman said, “all recommendations have been cleared with zero reservations and have corrected various inverted duty structure problems, classification related issues and that this rationalization exercise will bring predictability and stability of GST.” “These reforms have been carried out with a focus on the common man, and after a rigorous evaluation process in most sectors including healthcare, the rates have come down drastically, she added. Previously, medicines in India were taxed at 5 per cent for life-saving and essential drugs, and at 12 per cent for others but following the announcement all medicines will attract a standard duty of 5 per cent with extensions for several medicines specified at the end of this article. Welcoming the move, Sudarshan Jain, Secretary General, IPA said, “the decision to exempt life-saving and cancer medicines from GST, is a step that will bring direct relief to patients and their families. and, the reduction in GST on a wide range of medicines from 12 per cent to 5 per cent will further help to ease the overall treatment burden and make essential therapies more affordable.” Meanwhile, for companies, the clarity on a 5 per cent slab and exemptions removes long-standing ambiguity, enabling transparent pricing and better market planning. The move will expand access in semi-urban and rural markets, ease litigation, and free up resources for innovation, said Manoj Mishra, Partner and Tax Controversy Management Leader, Grant Thornton Bharat LLP. Notably, on the issue of inverted duty involving APIs and key starting materials—which are currently taxed at 18 per cent against 12 or 5 per cent for finished formulations—further clarity is awaited from the industry. ETPharma earlier reported that, in a letter to the Finance Minister, the national chemist body, the All India Organisation of Chemists and Druggists (AIOCD) had urged, “to bring all medicines including vitamins, probiotics, nutritional, food supplements under the 5 per cent GST slab. The rate rationalization comes days after Prime Minister Narendra Modi had pitched for introducing next-gen reforms across sectors to “increase ease of living for the common man and strengthen the economy.” However, this rationalization brings a revenue shortfall challenge for governments with states likely to bear a greater share of the burden, as they receive over 40 percent of the inter-state inflows in addition to their own SGST collections. Responding to a media query at the media briefing Arvind Shrivastava, Revenue Secretary said that, based on the consumption of FY23-24 the ministry has estimated that the net revenue implication of this proposal will be around Rs 48,000 crore. “However the exercise will trigger buoyancy effects and will have a positive impact on consumer and compliance. And therefore we believe this proposal will be fiscally sustainable both for centers and the states,” Shrivastava noted. ' S.no. Drug Indication Brand name and (Company) 1 Onasemnogene abeparvovec SMA (One-time gene therapy) Zolgensma (Novartis) 2 Asciminib Blood Cancer Scemblix (Novartis) 3 Mepolizumab Asthma Nucala (GSK) 4 Pegylated Liposomal Irinotecan Pancreatic Cancer Onivyde (Ipsen) 5 Daratumumab Cancer Darzalex (J&J subsidiary) 6 Daratumumab subcutaneous Cancer Darzalex Faspro (J&J subsidiary) 7 Teclistamab Blood Cancer Tecvayli (J&J subsidiary) 8 Amivantamab Lung Cancer Rybrevant (J&J subsidiary) 9 Alectinib Lung Cancer Alecensa (Roche) 10 Risdiplam SMA Evrysdi (Roche) 11 Obinutuzumab Blood Cancer Gazyva (Roche) 12 Polatuzumab vedotin Blood Cancer Polivy (Roche) 13 Entrectinib Cancer Rozlytrek (Roche) 14 Atezolizumab Cancer (PD-L1 immunotherapy) Tecentriq (Roche) 15 Spesolimab GPP flares Spevigo (Boehringer Ingelheim) 16 Velaglucerase Alpha Gaucher Vpriv (Takeda) 17 Agalsidase Alfa Fabry disease Replagal (Takeda) 18 Rurioctocog Alpha Pegol Hemophilia Adynovate (Takeda) 19 Idursulphatase Type II Mucopolysaccharidosis Elaprase (Takeda) 20 Alglucosidase Alfa Pompe Myozyme (Sanofi) 21 Laronidase Type I Mucopolysaccharidosis Aldurazyme (Sanofi) 22 Olipudase Alfa ASMD Xenpozyme (Sanofi) 23 Tepotinib Lung Cancer Tepmetko (Maerck KGaA) 24 Avelumab Cancer (PDL-1 immunotherapy) Bavencio (Pfizer) 25 Emicizumab Hemophilia Hemlibra (Roche subsidiary) 26 Belumosudil cGVHD - 27 Miglustat Gaucher Zavesca (J&J subsidiary) 28 Velmanase Alfa Alpha-mannosidosis - 29 Alirocumab Cholesterol lowering drug (LDL-C) Praluent (Sanofi) 30 Evolocumab Cholesterol lowering drug (LDL-C) Repatha (Amgen) 31 Cystamine Bitartrate Cystagon - 32 CI-Inhibitor injection Hereditary Angioedema - 33 Inclisiran Cholesterol lowering drug (LDL-C) Leqvio (Novartis) 34 Agalsidase Beta Fabry disease Fabrazyme (Sanofi) 35 Imiglucerase Gaucher Cerezyme (Sanofi) 36 Eptacog alfa activated recombinant coagulation factor VIIa Hemophilia NovoSeven Note: Above is the list of medicines exempted from GST tax recommended by the 56th GST Council Meet/ Source: PIB By Abhijeet Singh ,

Gene Therapy

02 Sep 2025

·www.fiercebiotech.com

CORRECTED: Chasing pharma heavyweights, Upstream posts phase 2 sinusitis win

While shares in Upstream fell 5.55% in premarket trading, the biotech\'s stock shot up nearly 20% to $20.26 by the end of the day Tuesday.\n Upstream Bio has sailed to a phase 2 win in sinusitis and plans to push its candidate forward against a competitive current.Investigators randomized 81 adults with chronic rhinosinusitis with nasal polyps (CRSwNP) to receive the anti-TSLP antibody verekitug or placebo every 12 weeks. After 24 weeks, Upstream linked the study drug to a 1.8-point placebo-adjusted reduction in endoscopic nasal polyp score (NPS) compared with baseline. The result caused the trial to meet its primary endpoint.Upstream posted hits on secondary endpoints, too. The biotech linked verekitug to a 0.8-point placebo-adjusted reduction from baseline in the patient-reported nasal congestion score (NCS). Upstream also hailed significant improvements in the need for systemic corticosteroids or nasal polyp surgeries and in total symptom scores. With no serious adverse events reported, the biotech believes it has the data to support talks with regulatory agencies about further development of verekitug. Upstream used phase 2 efficacy endpoints that, pending talks with regulators, could produce data to support submissions for approval. The biotech is advancing toward a market already served by Genentech and Novartis’ Xolair, Sanofi and Regeneron’s Dupixent (dupilumab) and GSK’s Nucala. Amgen and AstraZeneca have also filed for approval of TSLP drug Tezspire in the indication. While Tezspire targets the TSLP ligand, verekitug blocks the receptor. Upstream claims verekitug is about 300 times more potent than Tezspire.The emergence of a set of biologic treatments for CRSwNP over the past five years has set the bar verekitug needs to clear to compete. Asked about expectations for the phase 2 trial, Upstream CEO Rand Sutherland, M.D., quoted data on dupilumab.“Look at the label for dupilumab. There\'s about a 2-point change in the endoscopic nasal polyps score that was reported there. We think that that\'s probably relatively a floor for efficacy that we would want to see to be competitive,” Sutherland said at the J.P. Morgan Healthcare Conference in January. “I mean, there’s a little bit of room around that. We’ve powered to be even a little bit more robust than that.” Verekitug could have an advantage even if it only matches the efficacy of existing biologics. The antibody was given every 12 weeks in the phase 2 trial, while Dupixent and Tezspire were given every two weeks and every four weeks, respectively, in their phase 3 CRSwNP trials. Upstream’s market research found about 90% of patients would consider switching to a product with a less frequent dosing interval.William Blair analysts said the data drop \"largely comes in line with data from Tezspire, which showed roughly a 1.7-point improvement over placebo at week 24 that further improved to 2.07 at week 52.\" A sensitivity analysis of Upstream\'s results censoring patients receiving rescue steroids would boost the treatment difference to 1.9 points on the primary endpoint, likely surpassing Tezspire results at a similar timepoint, the analysts wrote in a Sept. 2 note. While shares in Upstream fell 5.55% in premarket trading, the biotech\'s stock shot up nearly 20% to $20.26 by the end of the day Tuesday. Upstream went public 11 months ago in an IPO that grossed $293 million. The biotech sold shares for $17 each in its IPO.Editor\'s note: This story has been corrected to include more than premarket trading changes.

Clinical ResultPhase 2IPOPhase 3

02 Sep 2025

·firstwordpharma.com

Upstream's TSLP-targeting drug verekitug hits goals in nasal polyp trial

Upstream Bio reported Tuesday that its experimental antibody verekitug hit the main goals of a mid-stage study in chronic rhinosinusitis with nasal polyps (CRSwNP) as the biotech looks to bolster its case that blocking the TSLP receptor could provide an edge over existing drugs.Amgen and AstraZeneca's Tezspire (tezepelumab-ekko), which blocks the TSLP ligand, is already under regulatory review for nasal polyps, putting it ahead of verekitug in a field that also includes established biologics such as Sanofi and Regeneron Pharmaceuticals' IL-4/IL-13 receptor blocker Dupixent (dupilumab), GSK's IL-5 antagonist Nucala (mepolizumab), and Roche and Novartis' anti-IgE antibody Xolair (omalizumab).Upstream is hoping to elbow its way into the market with a different approach – targeting the TSLP receptor instead of the ligand.Quarterly dosingThe 81-patient VIBRANT trial showed that a 100-mg subcutaneous dose given once every 12 weeks led to a placebo-adjusted drop of 1.8 points in endoscopic nasal polyp score (NPS) at the 24-week mark, compared to baseline, meeting the primary endpoint. Patients also reported less nasal congestion, with scores improving by 0.8 points compared to placebo, significant improvements in sinus opacification and a 76% reduction in the need for surgery or systemic corticosteroids. No serious safety concerns emerged."These results reinforce our earlier observations that verekitug's high potency, achieved through targeting the TSLP receptor, has the potential to translate into clinical attributes distinct from those offered by any currently available therapy," said Aaron Deykin, the company's chief medical officer and R&D head.Upstream has cited Phase Ib data suggesting that its receptor strategy may be about 300-fold more potent than Tezspire, while allowing for an extended dosing interval of up to six months.Dupixent, given every-other-week, is a commercial leader in the CRSwNP space, while Amgen and AstraZeneca are seeking approval for monthly Tezspire for the condition following the Phase III WAYPOINT readout in March. Meanwhile, aside from Nucala, GSK is also advancing depemokimab, an IL-5-targeting antibody with twice-yearly dosing. For insight into the competitive landscape, see – Spotlight On: More momentum for Tezspire? — AstraZeneca and Amgen's biologic therapy delivers compelling rhinosinusitis data.

Clinical ResultPhase 3Drug ApprovalADCPhase 1

100 Deals associated with Mepolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04923	Mepolizumab	R03DX09	DB06612

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	United States	GSK Plc	22 May 2025
Asthma	Japan	GlaxoSmithKline KK	25 Mar 2020
Chronic rhinosinusitis with nasal polyps	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Chronic rhinosinusitis with nasal polyps	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Chronic rhinosinusitis with nasal polyps	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Chronic rhinosinusitis with nasal polyps	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Severe asthma	United States	GlaxoSmithKline LLC	04 Nov 2015

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Eosinophilia	NDA/BLA	China	GlaxoSmithKline (China) Investment Co., Ltd.	14 Mar 2023
Asthma, Nasal Polyps, and Aspirin Intolerance	Phase 3	China	GSK Plc	22 Apr 2021
Asthma, Nasal Polyps, and Aspirin Intolerance	Phase 3	Japan	GSK Plc	22 Apr 2021
Asthma, Nasal Polyps, and Aspirin Intolerance	Phase 3	Russia	GSK Plc	22 Apr 2021
Eosinophilia	Phase 3	United Kingdom	GSK Plc	07 Sep 2020
Nasal Polyps	Phase 3	United States	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Argentina	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Australia	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Canada	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Germany	GSK Plc	25 May 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03494881 (CTgov)	Early Phase 1	Chronic Urticaria	10	Nucala	bdizmisgho = ggmkcmidmp fpcxvibbkx (puuychoxue, yqrsmewzgl - rvxottqshr) View more	-	27 Aug 2025
NCT04133909 (MATINEE, CTgov)	Phase 3	Pulmonary Disease, Chronic Obstructive	806	Mepolizumab (Mepolizumab 100 mg)	cdkoxwgxsu(tjahdmvbmz) = txkidnmmwt wnhkzilutq (yxudrffmlm, svpesuuqta - aovwsuotmf) View more	-	15 Aug 2025
				Placebo (Placebo)	cdkoxwgxsu(tjahdmvbmz) = eaqngxbyae wnhkzilutq (yxudrffmlm, hkswxgnveq - vnnhfkvcmr) View more
NCT04765722 (MUCOSA, ATS2025)	Phase 4	Refractory chronic cough sputum eosinophilia	30	Mepolizumab 100 mg	mbsgdqxkmq(svtftohbbw): % = 18.6 (95% CI, -23 to 82), P-Value = 0.44	Negative	16 May 2025
				Placebo
NEST (ATS2025)	Not Applicable	Severe asthma eosinophilic phenotype	306	Mepolizumab 100 mg	pbwupvaeld(ahybhjspsj) = kcaivukzfj jjvyuundhw (zgbjzmovhx ) View more	Positive	16 May 2025
				Maintenance OCS (mOCS)	pbwupvaeld(ahybhjspsj) = ehouvnnjpq jjvyuundhw (zgbjzmovhx ) View more
ATS2025	Not Applicable	Severe asthma	308	Mepolizumab	fcsjmpyxgf(dirpssxdmi) = njygzfsytt vvjphtnumv (nddfpuxjhq ) View more	Positive	16 May 2025
JPRN-UMIN000045021 (J-Real-Mepo Study, ATS2025)	Not Applicable	Galectin-10 (Gal10) \| TARC \| peripheral blood eosinophil counts	78	Mepolizumab	wdhxrbwjtx(ugkpavjohq) = rrwaoswiph yqrabpsrld (uzawcujisj ) View more	Positive	16 May 2025
NEST (ATS2025)	Not Applicable	Severe asthma eosinophilic phenotype	174	Mepolizumab	czkgjllrwc(yaxeltlxwo): incident rate ratio = 0.26 (95% CI, 0.18 - 0.36)	Positive	16 May 2025
				Previous Biologic Treatments
NCT03562195 (Pubmed \| Allergy Asthma Immunol Res)	Phase 3	Severe asthma	300	Mepolizumab	dndlspsrqj(wkwsacysgx) = iqoomxwwid nviolunrof (nggiobhifp ) View more	Positive	01 Jan 2025
				Placebo	dndlspsrqj(wkwsacysgx) = bcynazxjyh nviolunrof (nggiobhifp ) View more
NCT04276233 (PRISM, CTgov)	Phase 4	Asthma \| Eosinophilic Asthma	100	Mepolizumab	cdknfhtrfx = neajtzcixa omowsdgzoy (mjotqhfzyr, msaegpkxkz - xvupxkuhqq) View more	-	10 Dec 2024
NCT04607005 (MERIT, CTgov)	Phase 3	Asthma, Nasal Polyps, and Aspirin Intolerance \| Nasal Polyps \| Chronic rhinosinusitis with nasal polyps	169	Mepolizumab (Mepolizumab)	wgleocjoml(gfgcjzhykg) = qnxejquoyu vwgpsrnsao (owjhhoxreu, 0.164) View more	-	25 Nov 2024
				placebo (Placebo)	wgleocjoml(gfgcjzhykg) = iitdqcabwu vwgpsrnsao (owjhhoxreu, 0.164) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data